Abstract
Discussion Forum (0)
Obstetrics
Xylazine Use in Pregnancy: A Literature Review of Opioid Adulterant, Xylazine, in Pregnancy (ID: 1741)
Christiana Oyadeyi MD, MS, Waneeza Mughees MD, Dilruba Nakiboglu, Jason K. Baxter MD, Meena Khandelwal MD
Xylazine Use in Pregnancy: A Literature Review of Opioid Adulterant, Xylazine, in Pregnancy (ID: 1741)
Christiana Oyadeyi MD, MS, Waneeza Mughees MD, Dilruba Nakiboglu, Jason K. Baxter MD, Meena Khandelwal MD
INTRODUCTION:
Xylazine is an α-2 adrenergic agonist and tranquilizer that is approved by the U.S. Food and Drug Administration only for veterinary use. Studies involving xylazine use and its effect are mostly focused on animals and nonpregnant populations. Despite its widespread use in humans, rare cases have been reported in the literature. We desire to increase awareness of all providers on the effects and management of xylazine-adulterated fentanyl use in pregnancy.
METHODS:
PubMed, Google Scholar, and Embase were searched with keywords including “xylazine pregnancy,” “xylazine prenatal,” and “xylazine ulcers.” Studies were included if they researched the toxicity of xylazine use in pregnant humans, and the prevalence of xylazine-induced ulcers. Animal studies were not included in this study. Additionally, patient case series were reviewed with a focus on xylazine-induced ulcers, their complications, and management during pregnancy. Patient informed consent was obtained for the purposes of this study.
RESULTS:
Studies involving use of xylazine in humans have shown toxic effects including naloxone-refractory respiratory depression and central nervous system depression. Chronic use of xylazine-adulterated opioids has also been associated with wounds and skin ulcers. These skin ulcers in pregnancy are associated with additional complications like infection with methicillin-resistant Staphylococcus aureus infections and need for multidisciplinary management.
CONCLUSIONS/IMPLICATIONS:
This review highlights some challenges associated with xylazine use in pregnancy. Current studies involving effects of xylazine use in pregnancy are limited. With a rising opioid epidemic, there is a need for further studies, focusing on pregnancy outcomes to create recommendations on surveillance and management of xylazine use in pregnancy.
DOI: 10.1097/AOG.0000000000005918.036
Xylazine is an α-2 adrenergic agonist and tranquilizer that is approved by the U.S. Food and Drug Administration only for veterinary use. Studies involving xylazine use and its effect are mostly focused on animals and nonpregnant populations. Despite its widespread use in humans, rare cases have been reported in the literature. We desire to increase awareness of all providers on the effects and management of xylazine-adulterated fentanyl use in pregnancy.
METHODS:
PubMed, Google Scholar, and Embase were searched with keywords including “xylazine pregnancy,” “xylazine prenatal,” and “xylazine ulcers.” Studies were included if they researched the toxicity of xylazine use in pregnant humans, and the prevalence of xylazine-induced ulcers. Animal studies were not included in this study. Additionally, patient case series were reviewed with a focus on xylazine-induced ulcers, their complications, and management during pregnancy. Patient informed consent was obtained for the purposes of this study.
RESULTS:
Studies involving use of xylazine in humans have shown toxic effects including naloxone-refractory respiratory depression and central nervous system depression. Chronic use of xylazine-adulterated opioids has also been associated with wounds and skin ulcers. These skin ulcers in pregnancy are associated with additional complications like infection with methicillin-resistant Staphylococcus aureus infections and need for multidisciplinary management.
CONCLUSIONS/IMPLICATIONS:
This review highlights some challenges associated with xylazine use in pregnancy. Current studies involving effects of xylazine use in pregnancy are limited. With a rising opioid epidemic, there is a need for further studies, focusing on pregnancy outcomes to create recommendations on surveillance and management of xylazine use in pregnancy.
DOI: 10.1097/AOG.0000000000005918.036
Obstetrics
Xylazine Use in Pregnancy: A Literature Review of Opioid Adulterant, Xylazine, in Pregnancy (ID: 1741)
Christiana Oyadeyi MD, MS, Waneeza Mughees MD, Dilruba Nakiboglu, Jason K. Baxter MD, Meena Khandelwal MD
Xylazine Use in Pregnancy: A Literature Review of Opioid Adulterant, Xylazine, in Pregnancy (ID: 1741)
Christiana Oyadeyi MD, MS, Waneeza Mughees MD, Dilruba Nakiboglu, Jason K. Baxter MD, Meena Khandelwal MD
INTRODUCTION:
Xylazine is an α-2 adrenergic agonist and tranquilizer that is approved by the U.S. Food and Drug Administration only for veterinary use. Studies involving xylazine use and its effect are mostly focused on animals and nonpregnant populations. Despite its widespread use in humans, rare cases have been reported in the literature. We desire to increase awareness of all providers on the effects and management of xylazine-adulterated fentanyl use in pregnancy.
METHODS:
PubMed, Google Scholar, and Embase were searched with keywords including “xylazine pregnancy,” “xylazine prenatal,” and “xylazine ulcers.” Studies were included if they researched the toxicity of xylazine use in pregnant humans, and the prevalence of xylazine-induced ulcers. Animal studies were not included in this study. Additionally, patient case series were reviewed with a focus on xylazine-induced ulcers, their complications, and management during pregnancy. Patient informed consent was obtained for the purposes of this study.
RESULTS:
Studies involving use of xylazine in humans have shown toxic effects including naloxone-refractory respiratory depression and central nervous system depression. Chronic use of xylazine-adulterated opioids has also been associated with wounds and skin ulcers. These skin ulcers in pregnancy are associated with additional complications like infection with methicillin-resistant Staphylococcus aureus infections and need for multidisciplinary management.
CONCLUSIONS/IMPLICATIONS:
This review highlights some challenges associated with xylazine use in pregnancy. Current studies involving effects of xylazine use in pregnancy are limited. With a rising opioid epidemic, there is a need for further studies, focusing on pregnancy outcomes to create recommendations on surveillance and management of xylazine use in pregnancy.
DOI: 10.1097/AOG.0000000000005918.036
Xylazine is an α-2 adrenergic agonist and tranquilizer that is approved by the U.S. Food and Drug Administration only for veterinary use. Studies involving xylazine use and its effect are mostly focused on animals and nonpregnant populations. Despite its widespread use in humans, rare cases have been reported in the literature. We desire to increase awareness of all providers on the effects and management of xylazine-adulterated fentanyl use in pregnancy.
METHODS:
PubMed, Google Scholar, and Embase were searched with keywords including “xylazine pregnancy,” “xylazine prenatal,” and “xylazine ulcers.” Studies were included if they researched the toxicity of xylazine use in pregnant humans, and the prevalence of xylazine-induced ulcers. Animal studies were not included in this study. Additionally, patient case series were reviewed with a focus on xylazine-induced ulcers, their complications, and management during pregnancy. Patient informed consent was obtained for the purposes of this study.
RESULTS:
Studies involving use of xylazine in humans have shown toxic effects including naloxone-refractory respiratory depression and central nervous system depression. Chronic use of xylazine-adulterated opioids has also been associated with wounds and skin ulcers. These skin ulcers in pregnancy are associated with additional complications like infection with methicillin-resistant Staphylococcus aureus infections and need for multidisciplinary management.
CONCLUSIONS/IMPLICATIONS:
This review highlights some challenges associated with xylazine use in pregnancy. Current studies involving effects of xylazine use in pregnancy are limited. With a rising opioid epidemic, there is a need for further studies, focusing on pregnancy outcomes to create recommendations on surveillance and management of xylazine use in pregnancy.
DOI: 10.1097/AOG.0000000000005918.036
Xylazine Use in Pregnancy: A Literature Review of Opioid Adulterant, Xylazine, in Pregnancy
Connie Liao
Abstract
Discussion Forum (0)
Obstetrics
Xylazine Use in Pregnancy: A Literature Review of Opioid Adulterant, Xylazine, in Pregnancy (ID: 1741)
Christiana Oyadeyi MD, MS, Waneeza Mughees MD, Dilruba Nakiboglu, Jason K. Baxter MD, Meena Khandelwal MD
Xylazine Use in Pregnancy: A Literature Review of Opioid Adulterant, Xylazine, in Pregnancy (ID: 1741)
Christiana Oyadeyi MD, MS, Waneeza Mughees MD, Dilruba Nakiboglu, Jason K. Baxter MD, Meena Khandelwal MD
INTRODUCTION:
Xylazine is an α-2 adrenergic agonist and tranquilizer that is approved by the U.S. Food and Drug Administration only for veterinary use. Studies involving xylazine use and its effect are mostly focused on animals and nonpregnant populations. Despite its widespread use in humans, rare cases have been reported in the literature. We desire to increase awareness of all providers on the effects and management of xylazine-adulterated fentanyl use in pregnancy.
METHODS:
PubMed, Google Scholar, and Embase were searched with keywords including “xylazine pregnancy,” “xylazine prenatal,” and “xylazine ulcers.” Studies were included if they researched the toxicity of xylazine use in pregnant humans, and the prevalence of xylazine-induced ulcers. Animal studies were not included in this study. Additionally, patient case series were reviewed with a focus on xylazine-induced ulcers, their complications, and management during pregnancy. Patient informed consent was obtained for the purposes of this study.
RESULTS:
Studies involving use of xylazine in humans have shown toxic effects including naloxone-refractory respiratory depression and central nervous system depression. Chronic use of xylazine-adulterated opioids has also been associated with wounds and skin ulcers. These skin ulcers in pregnancy are associated with additional complications like infection with methicillin-resistant Staphylococcus aureus infections and need for multidisciplinary management.
CONCLUSIONS/IMPLICATIONS:
This review highlights some challenges associated with xylazine use in pregnancy. Current studies involving effects of xylazine use in pregnancy are limited. With a rising opioid epidemic, there is a need for further studies, focusing on pregnancy outcomes to create recommendations on surveillance and management of xylazine use in pregnancy.
DOI: 10.1097/AOG.0000000000005918.036
Xylazine is an α-2 adrenergic agonist and tranquilizer that is approved by the U.S. Food and Drug Administration only for veterinary use. Studies involving xylazine use and its effect are mostly focused on animals and nonpregnant populations. Despite its widespread use in humans, rare cases have been reported in the literature. We desire to increase awareness of all providers on the effects and management of xylazine-adulterated fentanyl use in pregnancy.
METHODS:
PubMed, Google Scholar, and Embase were searched with keywords including “xylazine pregnancy,” “xylazine prenatal,” and “xylazine ulcers.” Studies were included if they researched the toxicity of xylazine use in pregnant humans, and the prevalence of xylazine-induced ulcers. Animal studies were not included in this study. Additionally, patient case series were reviewed with a focus on xylazine-induced ulcers, their complications, and management during pregnancy. Patient informed consent was obtained for the purposes of this study.
RESULTS:
Studies involving use of xylazine in humans have shown toxic effects including naloxone-refractory respiratory depression and central nervous system depression. Chronic use of xylazine-adulterated opioids has also been associated with wounds and skin ulcers. These skin ulcers in pregnancy are associated with additional complications like infection with methicillin-resistant Staphylococcus aureus infections and need for multidisciplinary management.
CONCLUSIONS/IMPLICATIONS:
This review highlights some challenges associated with xylazine use in pregnancy. Current studies involving effects of xylazine use in pregnancy are limited. With a rising opioid epidemic, there is a need for further studies, focusing on pregnancy outcomes to create recommendations on surveillance and management of xylazine use in pregnancy.
DOI: 10.1097/AOG.0000000000005918.036
Obstetrics
Xylazine Use in Pregnancy: A Literature Review of Opioid Adulterant, Xylazine, in Pregnancy (ID: 1741)
Christiana Oyadeyi MD, MS, Waneeza Mughees MD, Dilruba Nakiboglu, Jason K. Baxter MD, Meena Khandelwal MD
Xylazine Use in Pregnancy: A Literature Review of Opioid Adulterant, Xylazine, in Pregnancy (ID: 1741)
Christiana Oyadeyi MD, MS, Waneeza Mughees MD, Dilruba Nakiboglu, Jason K. Baxter MD, Meena Khandelwal MD
INTRODUCTION:
Xylazine is an α-2 adrenergic agonist and tranquilizer that is approved by the U.S. Food and Drug Administration only for veterinary use. Studies involving xylazine use and its effect are mostly focused on animals and nonpregnant populations. Despite its widespread use in humans, rare cases have been reported in the literature. We desire to increase awareness of all providers on the effects and management of xylazine-adulterated fentanyl use in pregnancy.
METHODS:
PubMed, Google Scholar, and Embase were searched with keywords including “xylazine pregnancy,” “xylazine prenatal,” and “xylazine ulcers.” Studies were included if they researched the toxicity of xylazine use in pregnant humans, and the prevalence of xylazine-induced ulcers. Animal studies were not included in this study. Additionally, patient case series were reviewed with a focus on xylazine-induced ulcers, their complications, and management during pregnancy. Patient informed consent was obtained for the purposes of this study.
RESULTS:
Studies involving use of xylazine in humans have shown toxic effects including naloxone-refractory respiratory depression and central nervous system depression. Chronic use of xylazine-adulterated opioids has also been associated with wounds and skin ulcers. These skin ulcers in pregnancy are associated with additional complications like infection with methicillin-resistant Staphylococcus aureus infections and need for multidisciplinary management.
CONCLUSIONS/IMPLICATIONS:
This review highlights some challenges associated with xylazine use in pregnancy. Current studies involving effects of xylazine use in pregnancy are limited. With a rising opioid epidemic, there is a need for further studies, focusing on pregnancy outcomes to create recommendations on surveillance and management of xylazine use in pregnancy.
DOI: 10.1097/AOG.0000000000005918.036
Xylazine is an α-2 adrenergic agonist and tranquilizer that is approved by the U.S. Food and Drug Administration only for veterinary use. Studies involving xylazine use and its effect are mostly focused on animals and nonpregnant populations. Despite its widespread use in humans, rare cases have been reported in the literature. We desire to increase awareness of all providers on the effects and management of xylazine-adulterated fentanyl use in pregnancy.
METHODS:
PubMed, Google Scholar, and Embase were searched with keywords including “xylazine pregnancy,” “xylazine prenatal,” and “xylazine ulcers.” Studies were included if they researched the toxicity of xylazine use in pregnant humans, and the prevalence of xylazine-induced ulcers. Animal studies were not included in this study. Additionally, patient case series were reviewed with a focus on xylazine-induced ulcers, their complications, and management during pregnancy. Patient informed consent was obtained for the purposes of this study.
RESULTS:
Studies involving use of xylazine in humans have shown toxic effects including naloxone-refractory respiratory depression and central nervous system depression. Chronic use of xylazine-adulterated opioids has also been associated with wounds and skin ulcers. These skin ulcers in pregnancy are associated with additional complications like infection with methicillin-resistant Staphylococcus aureus infections and need for multidisciplinary management.
CONCLUSIONS/IMPLICATIONS:
This review highlights some challenges associated with xylazine use in pregnancy. Current studies involving effects of xylazine use in pregnancy are limited. With a rising opioid epidemic, there is a need for further studies, focusing on pregnancy outcomes to create recommendations on surveillance and management of xylazine use in pregnancy.
DOI: 10.1097/AOG.0000000000005918.036
{{ help_message }}
{{filter}}